Cannabis news and notes: New products, new research, new filings

Oct 15, 2020

Khronic A.I., a new artificial intelligence-based smartphone application that will allow users to identify different types of cannabis, is launching a Kickstarter campaign. According to a statement, “[t]he app is an equivalent of having a fully equipped laboratory inside a pocket, and in addition to identifying the type of a cannabis flower, the app also performs a quality check on it.” App creators are looking to raise funds for the project.

“This user-friendly app identifies, assesses, and generate reports regarding the type, quality, content, and categories of the cannabis flowers,” said Sam Paniagua, Khronic.AI spokesperson, in a statement. “Users simply have to point their phone camera at a cannabis flower and the app will do the rest. Furthermore, it will even predict the effects of a particular cannabis flower on the user.”

Can cannabis help with OCD?

A new study in the Journal of Affective Disorders found that cannabis use is associated with reduced symptoms of obsessive-compulsive disorder (OCD). According to the authors, “[u]sing a large dataset of medical cannabis users self-medicating for symptoms of OCD, we found that for the vast majority of cannabis use sessions individuals reported reductions in intrusions [unwanted thoughts or impulses], compulsions, and anxiety. … [R]esults indicated that after inhaling cannabis, ratings of intrusions were reduced by 49 percent, compulsions by 60 percent, and anxiety by 52 percent.” 

Consumption of cannabis containing higher concentrations of CBD was associated with decreases in compulsive behavior.

The authors also noted that “results from the present study indicate that inhaled cannabis may acutely reduce symptoms of OCD. While the symptom severity ratings were reduced by approximately 50 to 60 percent from immediately before to after cannabis use, there was evidence that cannabis-associated reductions in intrusions may diminish over time. Collectively these results indicate that cannabis may have short-term, but not long-term beneficial effects on symptoms of OCD.”

NORML’s Deputy Director Paul Armentano said in a statement: “Few studies have assessed the potential efficacy of cannabis for the mitigation of symptoms of OCD. As such, these findings, though somewhat limited by the study’s design, indicate that cannabis – and, in particular, varieties high in CBD – holds promise as a therapeutic option for OCD patients and should be further examined in a more rigorously designed controlled setting.”

Hemp industry challenges DEA’s regulatory overreach

According to a statement released by The Hemp Industries Association and a South Carolina-based hemp company, RE Botanicals, a new federal action was filed which, according to the two groups, is “aimed at clarifying the scope of the 2018 U.S. Farm Bill. This is the second federal action taken by the plaintiffs, who last month filed a petition for review of the DEA’s August 21 interim final rule (IFR) in a federal appeals court.”

“DEA’s latest jurisdictional overstep threatens every stage of the hemp production supply chain and jeopardizes the entire hemp industry,” according to the complaint. “If allowed to stand, DEA’s intrusion will undermine a lynchpin of the new hemp economy that has created tens of thousands of new jobs and provided a lucrative new crop for America’s struggling farmers.”

Add comment